Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna

Sep 18 2020

• By Derrick Gingery

Coronavirus mask — Pfizer wants to increase its clinical trial enrollment target to 44,000 in part to increase diversity. • Source: Shutterstock

Related Content

COVID-19 Vaccine Should Demonstrate At Least 50% Effectiveness, US FDA Says

Jul 01 2020

Moderna: Speed Of COVID-19 Vaccine Now Hinges On Enrolling The Right Patients

Jun 23 2020

Pfizer Appears Slightly Ahead Of Moderna In COVID-19 Vaccine Race

Sep 18 2020

COVID-19 Vaccine Sponsors’ Pledge To Wait For Phase III Helps US FDA

Sep 09 2020

After First COVID-19 Vaccine Approval, How Will Other Trials Maintain Placebo Control?

Sep 13 2020

US FDA Expects COVID-19 Vaccines To Meet ‘EUA Plus’ Standards, Marks Says

Sep 11 2020

Coronavirus Update: Rapid Restart For AZ’s Vaccine Trial, Pfizer Upsizes Its Phase III

Sep 14 2020

Related Companies

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Additional Topics

United States Coronavirus COVID-19 Clinical Trials Vaccines Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window